UNSPSC 51241545: Physostigmine/pilocarpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51241545 Physostigmine/pilocarpine is a Commodity code covering pharmaceutical active ingredients and finished drugs supplied through state and local health systems, institutional pharmacies, and correctional facilities. State and local governments procure this code primarily through multistate cooperative purchasing agreements, which pool demand across participating jurisdictions to negotiate volume-based pricing with manufacturers and authorized pharmaceutical wholesalers. The work involves supplying generic pharmaceutical products with specific National Drug Codes (NDCs), formulations, strengths, and dosage forms to meet inventory requirements across hospitals, clinics, public health agencies, and other government-operated facilities. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with authorized wholesalers equipped with chargeback systems, and meet FDA requirements including minimum shelf-life specifications. Issuing bodies include state departments of administration and health, county health systems, and institutional purchasing consortia operating on behalf of multiple member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract awards effective July 1, 2026 and participation spanning Minnesota and Oregon. Evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with administrative data format, EDI capability, and the required 3 percent administrative fee at 5 percent each. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with contract terms of two years for new responders and optional extensions at MMCAP's sole discretion.